Bausch Health Companies (BHC) Reports Q2 Revenues of $2.125B; Boosts FY18 Adj. EBITDA Guidance, Offers FY18 Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. DSX
2. GNK
3. INTC
4. SPCX
5. ACN
6. III
7. SAN
8. TTEC
9. SNY
10. DAL

Go back to Bausch Health Companies (BHC) Reports Q2 Revenues of $2.125B; Boosts FY18 Adj. EBITDA Guidance, Offers FY18 Revenue Outlook

Bausch Health Companies (BHC) PT Raised to $26 at RBC Capital

August 8, 2018 8:12 AM EDT

RBC Capital raised its price target on Bausch Health Companies (NYSE: BHC) to $26.00 (from $25.00) while maintaining a Sector Perform rating.

... More

Bausch Health Companies (BHC) PT Raised to $30 at Deutsche Bank

August 8, 2018 6:32 AM EDT

Deutsche Bank raised its price target on Bausch Health Companies (NYSE: BHC) to $30.00 (from $25.00) while maintaining a Buy rating.

Analsyt Gregg Gilbert commented, "BHC reported solid 2Q18 results, with revenue, EBITDA, and EPS coming in above our model (cash flow from ops... More

Bausch Health Co. Inc. (BHC) Subsidiaries, US WorldMeds LLC & Salix Pharma, Report U.S. Launch of LUCEMYRA (lofexidine) 0.18 Mg Tablets

August 6, 2018 7:11 AM EDT

US WorldMeds, LLC, and Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE: BHC), today announced the U.S. launch and availability of LUCEMYRA (lofexidine) 0.18 mg tablets, the first and only non-opioid medication indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

The Centers for Disease Control and Prevention estimates that more than 115 people in the U.S. die each day from opioid overdose.1 Often overlooked, opioid withdrawal is one of the most powerful barriers keeping people from discontinuing opioids. Many people have such difficulty... More